ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

ProQR Therapeutics N.V.NASDAQ: PRQR

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 105.36M shares rose 0.1% year over year, behind the +21.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at +13.7% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.1% toward the trailing-twelve-month pace of +21.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
105.36M+2.3% QoQ
Last fiscal yearDec 2025
105.33M+29.0% YoY
LTMMar 2026
105.94M+21.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.1%——
1 year+29.0%——
3-year CAGR+13.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
105.33M EUR
Year-over-year change
+29.0%
4-year CAGR
+13.2%

Weighted Avg Shares (Diluted) vs competitors

How PRQR compares with its peers on the latest reported figures

  • PRQR's LTM Mar 2026 weighted avg shares (diluted) of 105.94M shares is the 4th highest of the 11 companies compared; the peer median is 74.69M shares.
  • Its year-over-year change of +21.0% is the 5th highest of 11, against a peer median of +9.3%.
  • Over three fiscal years its annual growth of +13.7% compares with a peer median of +12.6%.
PRQR Competitors Peer median
Weighted Avg Shares (Diluted) for PRQR and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
IMMPImmutep LimitedFY2025145.58M +21.2%+19.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026105.94M +21.0%+13.7%
ZURAZura Bio LimitedLTM Mar 202698.81M +34.9%+76.1%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.1%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 202648.09M +39.5%+60.3%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +3.6%+9.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+0.4%
Peer median (excluding PRQR) 74.69M+9.3%+12.6%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.